


PHARMACEUTICAL 2017

NEUROPATHIX INC. Rank 269 of 313







PHARMACEUTICAL 2017

NEUROPATHIX INC. Rank 269 of 313



The relative strengths and weaknesses of NEUROPATHIX INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of NEUROPATHIX INC. compared to the market average is the variable Research and Development, increasing the Economic Capital Ratio by 493% points. The greatest weakness of NEUROPATHIX INC. is the variable Assets, Current, reducing the Economic Capital Ratio by 504% points.

The company's Economic Capital Ratio, given in the ranking table, is -685%, being 268% points below the market average of -417%.

Input Variable	Value in 1000 USD
Assets, Current	10
Cost of Goods Sold	21
Intangible Assets	0
Liabilities, Current	36
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	16
Other Liabilities	0
Other Net Income	0
Property and Equipment	0
Research and Development	0
Revenues	35
Selling, General and Administrative Expense	30

Output Variable	Value in 1000 USD
Assets	10
Liabilities	36
Expenses	67
Stockholders Equity	-26
Net Income	-32
Comprehensive Net Income	-32
Economic Capital Ratio	-685%